NASDAQ:ZLAB - Zai Lab Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$26.17 +0.44 (+1.71 %)
(As of 01/16/2019 01:43 PM ET)
Previous Close$25.73
Today's Range$25.79 - $26.93
52-Week Range$14.29 - $27.34
Volume9,169 shs
Average Volume163,994 shs
Market Capitalization$1.39 billion
P/E Ratio-11.31
Dividend YieldN/A
Beta0.98
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588

Debt

Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Book Value$4.77 per share
Price / Book5.49

Profitability

Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A

Miscellaneous

Employees88
Market Cap$1.39 billion
OptionableOptionable

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Zai Lab.

What price target have analysts set for ZLAB?

3 brokerages have issued 12-month price targets for Zai Lab's shares. Their forecasts range from $32.00 to $43.00. On average, they expect Zai Lab's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for Zai Lab.

What is the consensus analysts' recommendation for Zai Lab?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.

Has Zai Lab been receiving favorable news coverage?

Press coverage about ZLAB stock has trended positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zai Lab earned a news sentiment score of 2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the stock's share price in the immediate future.

Who are some of Zai Lab's key competitors?

Who are Zai Lab's key executives?

Zai Lab's management team includes the folowing people:
  • Dr. Ying Du, Chairman & CEO (Age 52)
  • Mr. Tao Fu, Pres, COO & Director (Age 46)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
  • Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 53)
  • Dr. Qi Liu, Chief Medical Officer of Oncology (Age 53)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $26.31.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $1.39 billion. The company earns $-50,380,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Zai Lab employs 88 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is http://www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]


MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel